TLX250 (177Lu)
Kidney Cancer (Clear Cell RCC) Therapy
Phase IActive
Key Facts
Indication
Kidney Cancer (Clear Cell RCC) Therapy
Phase
Phase I
Status
Active
Company
About Telix Pharmaceuticals
Telix Pharmaceuticals is a leader in the radiopharmaceutical space, focused on delivering precision oncology through targeted radiation. The company has achieved commercial success with its prostate cancer imaging agent Illuccix® and is advancing a deep pipeline of theranostic candidates, including its pivotal Phase III therapy program for prostate cancer (ProstACT). With a global operational footprint, including a major manufacturing facility in Belgium, Telix is positioned to scale its innovative platform across multiple high-need cancer indications.
View full company profile